Skip to content

The Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia

Pilot Study to Explore the Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05546112
Enrollment
30
Registered
2022-09-19
Start date
2022-10-04
Completion date
2022-12-31
Last updated
2022-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Keywords

Transcutaneous electric nerve stimulation, TENS, Insomnia, Trigeminal nerve stimulation

Brief summary

The purpose of this study is to explore the effects and safety of transcutaneous electrical nerve stimulation (TENS) at home for patients diagnosed with insomnia on the improvement of insomnia and nervous stability.

Interventions

DEVICETranscutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B

A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve

DEVICESham Stimulation using YPS-401B

A device that is attached in the same way as a real medical device, but actually applies a shum stimulus

Sponsors

Seoul National University Bundang Hospital
CollaboratorOTHER
Ybrain Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Men and women between the ages of 19 and under 65 * Those who meet the criteria for the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for Insomnia * Those with a score of 8 or higher based on the Korean version Insomnia severity index (ISI-K) * A person whose sleeping environment and habits are regular, usually between 9:00 p.m. and 1:00 a.m., go to bed, lie down for 7 to 10 hours, and wake up between 5 and 10 a.m. * In the case of patients who regularly take drugs for improving insomnia at least once a week, those who agree to discontinue taking the prohibited drugs in this study for a total of 5 weeks, 1 week to remove the drug effect after screening and 4 weeks for the clinical study period * Persons who do not have a reason to prohibit the use of electrotherapy that can significantly affect biomarkers in relation to this study * A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial

Exclusion criteria

* Those who have been diagnosed with sleep arousal disorders other than insomnia (hypersomnia disorder, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep arousal disorder, parasomnia) * Those who have insomnia due to physical illness or medications being taken * Patients with major medical and neuropsychiatric diseases other than sleep disorders * Persons who have had or are currently undergoing dental treatment with a history of implanting metallic materials into the upper body, such as the transcranial or face, neck, etc., where non-invasive electrical stimulation is difficult or impossible * Compliance was evaluated by writing a sleep diary for 1 week from the start of treatment, and if a sleep diary of 3 days or less was kept for 1 week, it was excluded from the study. * Those who have changed the type and dose of drugs used within the last 3 months, or the type and time of cognitive behavioral therapy * If you are currently registered in another clinical trial or use another clinical trial drug or device within 60 days from the time of screening

Design outcomes

Primary

MeasureTime frameDescription
Changes in Insomnia Severity Index (ISI)after 4 weeksChanges in Insomnia Severity Index (ISI) after 4 weeks from pretreatment:

Secondary

MeasureTime frameDescription
Remission rate of ISIafter 4 weeksRemission rate of ISI after 4 weeks compared to before treatment (Remission: ISI score of 7 or less)
Response rate of ISIafter 4 weeksResponse rate of ISI after 4 weeks compared to before treatment (Response: ISI change of more than 7 points or 50% or more decrease)
Changes in Pittsburgh Slepp Quality Index (PSQI)after 4 weeksChanges in Pittsburgh Slepp Quality Index (PSQI) after 4 weeks compared to before treatment
Changes in index of slepp diaryafter 4 weeksChanges in index of sleep diary (sleep latency, bedtime, sleep time) after 4 weeks compared to before treatment
Changes in EEG indexafter 4 weeksChanges in EEG index (absolute power, relative power) after 4 weeks compared to before treatment

Contacts

Primary ContactKiwon Lee, PhD
clinical.trials@ybrain.com+82-535-2871
Backup ContactJinuk Kim, PhD
jinuk.kim@ybrain.com+82-10-5185-4561

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026